Latest Articles
Biomarkers and Immunotherapy in Endometrial Cancer: Mechanisms and Clinical Applications - Frontiers
Biomarkers and Immunotherapy in Endometrial Cancer: Mechanisms and Clinical Applications Frontiers
Published: Oct. 6, 2025, 5:06 p.m.
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor - connectedtoindia.com
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor connectedtoindia.com
Published: Aug. 26, 2025, 4:39 a.m.
Immunotherapy for High-Grade Endometrial Stromal Sarcoma: A Narrative Review Bridging Molecular Insights to Clinical Translation - Frontiers
Immunotherapy for High-Grade Endometrial Stromal Sarcoma: A Narrative Review Bridging Molecular Insights to Clinical Translation Frontiers
Published: Aug. 25, 2025, 10:47 a.m.
Immunotherapy plus chemotherapy approved for endometrial cancer - The Pharmaceutical Journal
Immunotherapy plus chemotherapy approved for endometrial cancer The Pharmaceutical Journal
Published: Aug. 7, 2025, 2:48 p.m.
Breakthrough treatment combines immunotherapy and chemotherapy - National Health Executive
Breakthrough treatment combines immunotherapy and chemotherapy National Health Executive
Published: Aug. 7, 2025, 8:48 a.m.
NICE approves first immunotherapy combination for endometrial cancer - Wired Gov
NICE approves first immunotherapy combination for endometrial cancer Wired Gov
Published: Aug. 6, 2025, 1:13 p.m.
First immunotherapy combination for endometrial cancer approved by NICE - Oncology Central
First immunotherapy combination for endometrial cancer approved by NICE Oncology Central
Published: Aug. 6, 2025, 11:18 a.m.
First immunotherapy for advanced endometrial cancer approved in the UK - Open Access Government
First immunotherapy for advanced endometrial cancer approved in the UK Open Access Government
Published: Aug. 6, 2025, 8:50 a.m.
NICE approves first immunotherapy combination for endometrial cancer - NICE website
NICE approves first immunotherapy combination for endometrial cancer NICE website
Published: Aug. 5, 2025, 11 p.m.
B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight - The Malaysian Reserve
B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight The Malaysian Reserve
Published: July 24, 2025, 10:55 p.m.
Link copied to clipboard!